Visiogen Inc., an Irvine-based eye device maker, said Wednesday that it raised $24 million from its new and current investors.
The funding was the device maker’s first since late 2003, when it raised $16.5 million.
CMEA Ventures of San Francisco was the lead investor. Foundation Medical Partners of Rowayton, Conn., Three Arch Partners of Menlo Park, New Leaf Venture Partners of New York City and Menlo Park and Palo Alto-based Prospect Venture Partners also participated in the investment.
Visiogen said it will use the money to support continuing development of its Synchrony, an intraocular lens used in cataract surgery.
The company’s currently in third-phase clinical trials for Synchrony in the U.S., and has European regulatory clearance for the device.
